SCHEMBL27192085

SCHEMBL27192085

COC(=O)c1ccc(Br)cc1NC(=O)Oc1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.74
KDM4E B2RXH2 6/20 0.74
GAA P10253 4/20 0.74
HPGD P15428 3/20 0.74
GLA P06280 1/20 0.74
ATM Q13315 1/20 0.74
CYP1A2 P05177 2/20 0.56
KMT2A Q03164 4/20 0.56
MAPT P10636 4/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
MEN1 O00255 1/20 0.56
NPC1 O15118 1/20 0.56
CYP2C9 P11712 1/20 0.56
ALOX12 P18054 1/20 0.56
CYP2C19 P33261 1/20 0.56
ABCG2 Q9UNQ0 2/20 0.55
HSD17B10 Q99714 2/20 0.45
TSHR P16473 2/20 0.45
MAPK10 P53779 1/20 0.45
RAB9A P51151 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3789176 0.85 ALDH1A1 (0.76) ALDH1A1KDM4EGAAHPGDGLA
SCHEMBL3782285 0.85 ALDH1A1 (0.76) ALDH1A1KDM4EGAAHPGDGLA
SCHEMBL3780392 0.84 ALDH1A1 (0.74) ALDH1A1KDM4EGAAHPGDGLA
SCHEMBL31681219 0.83 KDM4E (0.65) ALDH1A1KDM4EGAAHPGDGLA
SCHEMBL3783571 0.83 KDM4E (0.78) ALDH1A1KDM4EGAAHPGDGLA
SCHEMBL2275624 0.81 KDM4E (0.64) ALDH1A1KDM4EGAAHPGDCYP1A2
SCHEMBL21198213 0.80 KMT2A (0.56) ALDH1A1KDM4EGAAHPGDGLA
SCHEMBL3990612 0.78 ABCG2 (0.56) ALDH1A1KDM4EGAAHPGDCYP1A2
SCHEMBL29476211 0.78 ABCG2 (0.56) ALDH1A1KDM4EGAAHPGDCYP1A2
SCHEMBL459443 0.78 ABCG2 (0.51) ALDH1A1KDM4EGAAHPGDGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12410183-B2 Sars-cov2 main protease inhibitors GILEAD SCIENCES, INC. (US) 2025-09-09 US disclosed
EP-4565574-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. (US) 2025-06-11 EP disclosed
US-20250042915-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. 2025-02-06 US disclosed
US-12091420-B2 SARS-COV2 main protease inhibitors GILEAD SCIENCES, INC. (US) 2024-09-17 US disclosed
US-20240239807-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. 2024-07-18 US disclosed
US-20240116946-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. 2024-04-11 US disclosed
WO-2024031089-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250042915-A1 SARS-COV2 MAIN PROTEASE INHIBITORS ACE2, TMPRSS2, ACE ALDH1A1 3259/4885KDM4E 3744/4885GAA 180/4885
US-12091420-B2 SARS-COV2 main protease inhibitors ACE2, TMPRSS2, ACE ALDH1A1 3259/4885KDM4E 3744/4885GAA 180/4885
US-20240116946-A1 SARS-COV2 MAIN PROTEASE INHIBITORS ACE2, TMPRSS2, ACE ALDH1A1 3259/4885KDM4E 3744/4885GAA 180/4885
US-12410183-B2 Sars-cov2 main protease inhibitors ACE2, TMPRSS2, ACE ALDH1A1 3259/4885KDM4E 3744/4885GAA 180/4885
US-20240239807-A1 SARS-COV2 MAIN PROTEASE INHIBITORS ACE2, TMPRSS2, ACE ALDH1A1 3259/4885KDM4E 3744/4885GAA 180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.